These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 885093)

  • 1. Relative unresponsiveness of obese diabetic compared to obese non-diabetic subjects to the weight-reducing effect of fenfluramine.
    Otim MA
    East Afr Med J; 1977 Feb; 54(2):91-5. PubMed ID: 885093
    [No Abstract]   [Full Text] [Related]  

  • 2. Phenformin compared with fenfluramine in the treatment of obese diabetic patients.
    Kesson CM; Ireland JT
    Practitioner; 1976 May; 216(1295):577-80. PubMed ID: 781656
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessment of new formulation of fenfluramine in the management of the obese, diabetic African.
    Wilton D
    Postgrad Med J; 1975; 51 Suppl 1():138-9. PubMed ID: 1219673
    [No Abstract]   [Full Text] [Related]  

  • 4. [The treatment of the obese non-insulin-dependent patient with d-fenfluramine].
    Daniele E; Coco MP
    Clin Ter; 1996 Apr; 147(4):199-204. PubMed ID: 8766352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenfluramine in management of obese diabetics.
    Misra NP; Bhambal SA; Yesikar SS; Bellani RK
    J Assoc Physicians India; 1980 Sep; 28(9):287-95. PubMed ID: 7007309
    [No Abstract]   [Full Text] [Related]  

  • 6. [Hypoglycemic action of fenfluramine in obese diabetics].
    De Sereday MS; Efron HR; De Compte DV; Raffo del Campo MA
    Prensa Med Argent; 1971 Jul; 58(20):1030-3. PubMed ID: 4938286
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful appetite suppression therapy with fenfluramine and phentermine in the obese diabetic transplant patient.
    Khan M; Lum CT; Rao V
    Transplant Proc; 1995 Feb; 27(1):975-6. PubMed ID: 7879251
    [No Abstract]   [Full Text] [Related]  

  • 8. [Is fenfluramine suitable as a therapeutic principle in obese aged diabetics? (end)].
    Förster H; Huth K; Koch E; Tunali G
    Fortschr Med; 1979 Feb; 97(6):259-62. PubMed ID: 428867
    [No Abstract]   [Full Text] [Related]  

  • 9. [Experience with the appetite depressant, fenfluramine hydrochloride, in adiposity].
    Liebermeister H; Probst G; Jahnke K
    Med Klin; 1969; 64(26):1201-7. PubMed ID: 5807324
    [No Abstract]   [Full Text] [Related]  

  • 10. [A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group].
    Enzi G
    Ter Arkh; 1997; 69(5):71-5. PubMed ID: 9235665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged-action fenfluramine in non-diabetic patients with refractory obesity.
    Galloway DB; Logie AW; Petrie JC
    Postgrad Med J; 1975; 51 Suppl 1():155-7. PubMed ID: 768957
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term treatment with fenfluramine in obese subjects.
    Sensi S; Della Loggia F; Del Ponte A; Guagnano MT
    Int J Clin Pharmacol Res; 1985; 5(4):247-53. PubMed ID: 4055167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Activity of fenfluramine in obese subjects. Relation between dosage, plasma concentration of the drug and its effect on weight loss].
    Magnoni V; Boni S; Bonini LM; Zecca L; Bareggi SR
    Minerva Med; 1982 Jun; 73(24):1703-10. PubMed ID: 7088388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A trial of fenfluramine (PACaps) and diet in overweight diabetic patients.
    Wells HM
    Postgrad Med J; 1975; 51 Suppl 1(593):137. PubMed ID: 1219672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of phenethylbiguanide on body weight and some serum lipid indices in obese subjects, obese diabetics and obese subjects with potential diabetes].
    Pompei A; Marcenaro A; Foppiani E; Jacopino GE
    Clin Ter; 1969 Dec; 51(6):541-60. PubMed ID: 5371379
    [No Abstract]   [Full Text] [Related]  

  • 16. [Is fenfluramine a suitable therapeutic principle in obese aged diabetics?].
    Förster H; Huth K; Koch E; Tunali G
    Fortschr Med; 1979 Jan; 97(4):169-74. PubMed ID: 422110
    [No Abstract]   [Full Text] [Related]  

  • 17. [Chronotherapy of obesity. I. Effect of fenfluramine on the decrease of adipose mass in the obese, in relation to the time of administration].
    Guagnano MT; Di Vincenzo M; Sensi S
    Boll Soc Ital Biol Sper; 1982 Jun; 58(12):736-9. PubMed ID: 7104096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Influence of fenfluramine on the weekly curve of weight loss during obesity].
    Cabezas Cerrato J; Gómez Pérez M; Marco-Mur AL; Camarero E; Fernández-Cruz A
    Rev Clin Esp; 1974 Jan; 132(1):47-52. PubMed ID: 4840227
    [No Abstract]   [Full Text] [Related]  

  • 19. [The effect of body weight on insulin activity].
    Sindelka G; Skrha J; Prázný M; Hilgertová J
    Vnitr Lek; 1999 Sep; 45(9):540-4. PubMed ID: 10951879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Added benfluorex in obese insulin-requiring type 2 diabetes.
    Leutenegger M; Bauduceau B; Brun JM; Guillon-Metz F; Martin C; Nicolino-Peltier C; Richard JL; Vannereau D
    Diabetes Metab; 1998 Feb; 24(1):55-61. PubMed ID: 9534010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.